An Open-Label, Fixed Sequence, Clinical Drug Interaction Study to Evaluate the Time-Dependent Inhibition Potential of Vonoprazan on a Sensitive CYP3A4 Substrate, Midazolam, in Healthy Volunteers
Latest Information Update: 20 Mar 2023
At a glance
- Drugs Midazolam (Primary) ; Vonoprazan (Primary)
- Indications Duodenal ulcer; Erosive oesophagitis; Gastric ulcer; Gastro-oesophageal reflux; Gastrointestinal disorders; Helicobacter infections; Peptic ulcer; Reflux oesophagitis
- Focus Pharmacokinetics
- Sponsors Phathom Pharmaceuticals
- 30 Nov 2020 Status changed from active, no longer recruiting to completed.
- 09 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 23 Oct 2020 Planned End Date changed from 11 Nov 2020 to 25 Nov 2020.